Gene therapy for sickle cell disease shows curative potential healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, today announced the selection of an.
Share this article
Share this article
NEW YORK and BASEL, Switzerland, May 4, 2021 /PRNewswire/ Aruvant Sciences ( Aruvant ), a private company focused on developing gene therapies for rare diseases, announced it has added eleven scientists to its manufacturing, preclinical and clinical teams, a major milestone in the company s strategy to build a beginning-to-end internal-external supply model led by its pioneering cell and gene therapy expertise. Additional expansion in clinical, technical, operational and quality areas will continue throughout the year as the company prepares for a pivotal study of ARU-1801, a one-time gene therapy designed to cure sickle cell disease. Having the right talent is essential to the successful development and manufacturing of our potentially curative product candidates, said Will Chou, M.D., chief executive officer at Aruvant. Adding this group of scientists, who have deep gene therapy experience, creates an important foundation that positio
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Aruvant Announces Oral Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting
April 27, 2021 GMT
(PRNewsfoto/Aruvant Sciences)
NEW YORK and BASEL, Switzerland, April 27, 2021 /PRNewswire/ Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies for rare diseases, today announced that data on ARU-1801, a potentially curative gene therapy for sickle cell disease (SCD), will be delivered in an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. Dr. Punam Malik, director of the Cincinnati Comprehensive Sickle Cell Center and program leader of the Hematology and Gene Therapy Program at the Cincinnati Children’s Hospital Medical Center, will present data from the ARU-1801 Phase 1/2 MOMENTUM clinical trial during ASGCT, which will take place virtually from May 11 to May 14, 2021.
Share this article
Share this article
NEW YORK and BASEL, Switzerland, April 23, 2021 /PRNewswire/ Aruvant Sciences ( Aruvant ), a private company focused on developing gene therapies for rare diseases, today announced the appointment of Meghan Kelton, executive director, human resources (HR), and E. Blair Clark-Schoeb, senior vice president, communications, to the Aruvant leadership team. Ms. Kelton s HR experience in gene therapy and Ms. Clark-Schoeb s public company and rare disease communications know-how will be critical as we take Aruvant to the next level, said Will Chou, M.D., chief executive officer of Aruvant. With the company in a growth phase, Ms. Kelton will focus on building out the technical, development and manufacturing functions and creating an inclusive environment needed to support an engaged workforce. Ms. Clark-Schoeb will lead our internal and external communications efforts, investor relations, media effort and work with the rare disease and sick